Patient characteristics at diagnosis
| Patient characteristics (n = 241) . | Patients with deletions (n = 39) . | Patients without deletions (n = 202) . |
|---|---|---|
| Sex (M/F) | 23/16 | 110/92 |
| Median age, y (interquartile range) | 50 (35-59) | 47 (37-57) |
| No. (%) with splenomegaly | 24 (65%) | 120 (60%) |
| Median hemoglobin g/L (interquartile range) | 100.0 (83.5-120.5) | 114.5 (97.7-129.2) |
| Median WCC × 109/L (interquartile range) | 165.0 (60.4-359.0) | 140 (53.2-234.5) |
| Median platelet count × 109/L (interquartile range) | 389 (286-655) | 405 (266-606) |
| Median peripheral blood blasts as % of WCC (interquartile range) | 1.0 (0-3.2) | 1.0 (0-4.0) |
| Sokal score: number of patients assessed | 37 | 193 |
| High | 14 (38%) | 67 (34%) |
| Intermediate | 10 (27%) | 63 (33%) |
| Low | 13 (35%) | 63 (33%) |
| Hasford score: number of patients assessed | 32 | 178 |
| High | 7 (22%) | 39 (21%) |
| Intermediate | 15 (48%) | 69 (39%) |
| Low | 10 (30%) | 70 (40%) |
| Treatment type | ||
| Interferon-α +/− chemotherapy | 15 (39%) | 116 (57%) |
| Oral chemotherapy | 22 (56%) | 81 (40%) |
| Bone marrow transplantation | 12 (31%) | 63 (31%) |
| Karyotype | ||
| Classical Ph | 23 (59%) | 177 (88%) |
| Variant Ph | 16 (41%) | 25 (12%) |
| Phase of disease at diagnosis (%) | ||
| Chronic phase | 37 (95%) | 191 (94.5%) |
| Accelerated phase | 1 (2.5%) | 6 (2.9%) |
| Blast crisis | 1 (2.5%) | 5 (2.6%) |
| Patients alive (%) | 6 (16%) | 84 (41%) |
| Censored* | 13 (33%) | 68 (34%) |
| Dead | 20 (51%) | 50 (25%) |
| Patient characteristics (n = 241) . | Patients with deletions (n = 39) . | Patients without deletions (n = 202) . |
|---|---|---|
| Sex (M/F) | 23/16 | 110/92 |
| Median age, y (interquartile range) | 50 (35-59) | 47 (37-57) |
| No. (%) with splenomegaly | 24 (65%) | 120 (60%) |
| Median hemoglobin g/L (interquartile range) | 100.0 (83.5-120.5) | 114.5 (97.7-129.2) |
| Median WCC × 109/L (interquartile range) | 165.0 (60.4-359.0) | 140 (53.2-234.5) |
| Median platelet count × 109/L (interquartile range) | 389 (286-655) | 405 (266-606) |
| Median peripheral blood blasts as % of WCC (interquartile range) | 1.0 (0-3.2) | 1.0 (0-4.0) |
| Sokal score: number of patients assessed | 37 | 193 |
| High | 14 (38%) | 67 (34%) |
| Intermediate | 10 (27%) | 63 (33%) |
| Low | 13 (35%) | 63 (33%) |
| Hasford score: number of patients assessed | 32 | 178 |
| High | 7 (22%) | 39 (21%) |
| Intermediate | 15 (48%) | 69 (39%) |
| Low | 10 (30%) | 70 (40%) |
| Treatment type | ||
| Interferon-α +/− chemotherapy | 15 (39%) | 116 (57%) |
| Oral chemotherapy | 22 (56%) | 81 (40%) |
| Bone marrow transplantation | 12 (31%) | 63 (31%) |
| Karyotype | ||
| Classical Ph | 23 (59%) | 177 (88%) |
| Variant Ph | 16 (41%) | 25 (12%) |
| Phase of disease at diagnosis (%) | ||
| Chronic phase | 37 (95%) | 191 (94.5%) |
| Accelerated phase | 1 (2.5%) | 6 (2.9%) |
| Blast crisis | 1 (2.5%) | 5 (2.6%) |
| Patients alive (%) | 6 (16%) | 84 (41%) |
| Censored* | 13 (33%) | 68 (34%) |
| Dead | 20 (51%) | 50 (25%) |
Treatment and survival data were available for 241 of 253 patients. Information sufficient to perform Sokal and Hasford scores was available in 230 and 210 patients, respectively. Some patients received oral chemotherapy (hydroxyurea or busulphan) and IFN-α prior to bone marrow transplantation and so the sum of the patients in the treatment section is greater than 100%.
WCC indicates white cell count.
For patients with deletions, 13 patients were censored, 12 of whom were alive and received a bone marrow transplant; 1 patient died from a cause unrelated to CML. For patients without deletions, 68 patients were censored, of whom 63 were alive and received a bone marrow transplant and 5 died from causes unrelated to CML.